In breast cancer BT-474 cells, both astemizole (a Kv10.1/EAG1 K+ channel blocker) and gefitinib induced cell cycle arrest and inhibited proliferation dose dependently (IC50 = 1.72 μM and 0.51 μM, respectively). The gene discussed is KCNH1; the disease is breast carcinoma.